Group 1 - Zhiyun Health (09955) announced the appointment of Ms. Hu Yue as an executive director and a member of the board nomination committee, effective from December 27, 2025 [1] - Ms. Zuo Yinghui has resigned from her position as an executive director and will no longer be a member of the nomination committee, effective from December 27, 2025, due to her desire to devote more time to other professional matters [1]

Group 1 - The company announced the appointment of Ms. Hu Yue as an executive director and a member of the board nomination committee, effective from December 27, 2025 [1] - Ms. Zuo Yinghui has resigned from her position as an executive director and will no longer be a member of the nomination committee, also effective from December 27, 2025, due to her desire to dedicate more time to other professional matters [1]

（於開曼群島註冊成立的有限公司） （股份代號：9955） 董事名單與其角色和職能 智雲健康科技集團*（「本公司」）董事（「董事」）會（「董事會」）成員如下。 執行董事 匡明先生 （董事長兼行政總裁） 胡悅女士 獨立非執行董事 洪偉力博士 張賽音先生 Ang Khai Meng先生 董事會轄下設有三個董事會委員會。下表提供了各董事任職的委員會成員資料。 | 董事會委員會 | 審核委員會 | 薪酬委員會 | 提名委員會 | | --- | --- | --- | --- | | 董事 | | | | | 匡明先生 | | 成員 | 主席 | | 胡悅女士 | | | 成員 | | 洪偉力博士 | 成員 | 主席 | 成員 | | 張賽音先生 | 主席 | 成員 | 成員 | | Ang Khai Meng先生 | 成員 | | 成員 | 2025年12月28日 * 僅供識別 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：9955） 董事變更 及董事會委員會組成變更 委任執行董事 智雲健康科技集團*（「本公司」，連同其子公司及併表聯屬實體，統稱「本集團」） 董事（「董事」）會（「董事會」）欣然宣佈，胡悅女士（「胡女士」）已獲委任為執行 董事兼董事會提名委員會（「提名委員會」）成員，自2025年12月27日起生效。 胡女士的履歷詳情載列如下： 執行董事辭任 董事會宣佈，左穎暉女士（「左女士」）已辭任執行董事職務，並不再為提名委員 會成員，自2025年12月27日起生效，原因為彼希望投入更多時間於其他專業事 務。左女士已確認，彼與董事會或本公司並無任何爭議或意見分歧，且概無有 關彼辭任的任何事宜須提請股東或聯交所垂注。 胡悅女士，50歲，自2018年9月起擔任本集團副總裁兼人力資源主管，主要負 責管理本集團的人力資源及戰略規劃。 於加入本集團前，胡女士於1997年7月至2005年 ...

Core Insights - The article highlights that Zhiyun Health (09955.HK) has been awarded the "Annual Transformation Pioneer Award" for its outstanding performance in strategic transformation, business restructuring, and sustainable growth in a dynamic market environment [1][2]. Group 1: Strategic Focus and Transformation - Zhiyun Health has shifted from a scale expansion model to a focus on "AI SaaS + P2M" as its core growth strategy, emphasizing high-quality and high-value growth [2]. - The company has strategically divested from non-core businesses, such as medical supplies and consumables, to concentrate resources on digital chronic disease management, thereby clarifying its strategic direction [3]. Group 2: Financial Performance and Validation - The mid-2025 financial report shows a 20.3% year-on-year growth in revenue after excluding the impact of divested businesses, indicating strong internal growth in core operations [4]. - The gross profit margin reached 37.1%, an increase of over 16 percentage points year-on-year, with adjusted gross margins at 49.9%, reflecting a successful shift from a scale-driven to a quality-driven business model [4]. Group 3: Cash Flow and Sustainability - For the first half of 2025, Zhiyun Health achieved a positive operating cash flow of 28.65 million, marking its first positive cash flow since going public, which validates its high-value strategic focus and demonstrates its self-sustaining capabilities [5][6]. Group 4: Dual-Engine Growth Model - The "AI SaaS + P2M" dual-engine model supports the company's transformation and long-term market outlook, with the SaaS system covering over 2,700 hospitals and nearly 270,000 pharmacies nationwide, establishing a robust digital service network [7]. - The P2M model, which links patient needs directly to the pharmaceutical industry, generated revenue of 260 million in the first half of 2025, a year-on-year increase of 142.1%, and has become a significant growth driver for the company [8]. Group 5: Technological Advancements - Zhiyun Health continues to deepen its core technology exploration, with self-developed models like "Zhiyun Medical Brain" and ClouD GPT enhancing operational efficiency and aiding in clinical diagnosis and research innovation [9]. Group 6: Future Outlook - The award signifies recognition of Zhiyun Health's past transformation and sets the stage for future endeavors, as the company aims to solidify its leading position in digital chronic disease management and leverage technology to reshape healthcare value [10].

Core Insights - The article highlights that Zhiyun Health (09955.HK) won the "Annual Transformation Pioneer Award" for its outstanding performance in strategic transformation, business restructuring, and sustainable growth [1][4] - The award recognizes companies that achieve high-quality development and create long-term value through proactive changes in a dynamic market environment [1] Strategic Focus and Financial Transformation - Zhiyun Health has shifted from a scale expansion model to a focus on "AI SaaS + P2M" for high-quality growth [4] - The company has divested non-core businesses, such as medical supplies, to concentrate resources on digital chronic disease management, marking a strategic focus rather than mere contraction [5] Financial Performance - In the first half of 2025, Zhiyun Health reported a 20.3% year-on-year revenue growth after excluding the impact of divested businesses, demonstrating resilience in core business growth [6] - The gross margin reached 37.1%, an increase of over 16 percentage points year-on-year, indicating a successful shift from scale-driven to quality-driven business [6] - The company achieved a historic positive operating cash flow of 28.65 million yuan, marking its first positive cash flow since listing, validating its high-value strategy [7] AI SaaS + P2M Dual-Engine Model - Zhiyun Health has developed a dual-engine model of "AI SaaS + P2M," which enhances its business transformation and provides a sustainable core momentum [9] - The company's SaaS systems cover over 2,700 hospitals and nearly 270,000 pharmacies, establishing a vast digital service network that supports data accumulation and patient insights [10] - The P2M model generated 260 million yuan in revenue in the first half of 2025, a 142.1% year-on-year increase, and has become a profitable growth driver [11] Technological Advancements - The company continues to explore core technologies, with its self-developed "Zhiyun Medical Brain" and various AI models enhancing operational efficiency and aiding in diagnosis and research [12] - The integration of advanced AI technology is crucial for the effective operation of the dual-engine model and building long-term competitive barriers [12] Future Outlook - With the recognition of the "Annual Transformation Pioneer Award," Zhiyun Health has successfully transitioned from a digital service provider to a chronic disease management ecosystem re-builder [14] - The company aims to solidify its leading position in digital chronic disease management while leveraging technology to reconstruct medical value and empower the future of the industry [14]

Group 1 - The "Annual Transformation Pioneer Award" recognizes companies that demonstrate adaptability to dynamic environmental changes and achieve long-term sustainable, high-quality development [1] - The award highlights companies that create value through transformation, maintain innovation vitality, and positively impact industrial upgrades, reflecting excellence in financial performance, innovation, resilience, and a balance of social and economic benefits [1] - Six companies were awarded the "Annual Transformation Pioneer Award": CANG.US, 01911.HK, AXG.US, 09878.HK, 01783.HK, and 09955.HK, listed in alphabetical order [1] Group 2 - The "Golden Award" aims to create a reference value ranking of listed companies and unicorns in the investment community, covering all listed companies on major exchanges including HKEX, SSE, SZSE, NYSE, and NASDAQ [2]

Group 1 - The "Annual Transformation Pioneer Award" recognizes companies that demonstrate adaptability to dynamic environmental changes and the ability to achieve long-term sustainable and high-quality development [1] - The award highlights companies that create value through transformation, maintain innovation vitality, and positively impact industrial upgrades, while balancing social and economic benefits [1] - Six companies were awarded the "Annual Transformation Pioneer Award": CANG.US, 01911.HK, AXG.US, 09878.HK, 01783.HK, and 09955.HK, listed in alphabetical order [1] Group 2 - The "Golden Grid Award" aims to create a reference value ranking for listed companies and unicorns in the investment community, covering all listed companies on major exchanges including HKEX, SSE, SZSE, NYSE, and NASDAQ [2]

Core Insights - The article highlights the rapid transformation of the healthcare industry through AI, particularly focusing on the success of Ping An Good Doctor (1833.HK), which has achieved over 135% growth in the Hong Kong stock market this year, making it a leader in the AI healthcare sector [1][6]. Industry Overview - The integration of AI into the healthcare sector is seen as a critical area, with significant implications for efficiency and health outcomes [1]. - The Chinese AI healthcare market is projected to reach 115.7 billion yuan by 2025 and 159.8 billion yuan by 2028, with a stable compound annual growth rate of 10.5% from 2022 to 2028 [5]. Policy Support - The Chinese government has officially recognized the integration of AI with the real economy as a national strategy, with specific goals set for AI applications in healthcare by 2027 and 2030 [3][4]. Company Analysis: Ping An Good Doctor - Ping An Good Doctor has developed a comprehensive "machine + human + ecosystem" model, distinguishing itself from other platforms that primarily focus on e-commerce or single online services [7][8]. - The company utilizes its proprietary "Ping An Medical Assistant" model, trained on extensive medical databases and online consultation data, to offer a diverse range of AI healthcare products [8]. - The AI-driven model emphasizes human-machine collaboration, enhancing the quality and efficiency of medical services, with reported improvements in treatment accuracy and cost reductions [9][10]. Competitive Advantage - Ping An Good Doctor benefits from a robust ecosystem supported by the Ping An Group, which includes a vast network of healthcare providers and resources, enhancing its service delivery capabilities [10][11]. - The company's revenue structure is diversified, with significant contributions from medical services, health services, and elderly care, contrasting with competitors heavily reliant on drug sales [12]. Market Sentiment and Valuation - Institutional investors have shown strong interest in Ping An Good Doctor, with significant net inflows and increased stock holdings, indicating a positive market sentiment [15][19]. - Analysts have recognized the strategic positioning of the company within the healthcare and insurance sectors, leading to upward revisions in target prices by various brokerage firms [20][22]. Conclusion - The article concludes that Ping An Good Doctor's unique approach and integration of AI into healthcare not only positions it favorably in the market but also sets a benchmark for sustainable growth and innovation in the industry [25].

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 智雲健康科技集團 (於開曼群島註冊成立的有限公司) 呈交日期: 2025年12月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09955 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.0001 | USD | | 100,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 1,000,000,000 | USD | | 0.0001 | USD | | ...